World Generic Medicines 2016 Speakers

Claudio Albrecht has more than 26 years' experience in the global pharmaceutical and generics industries. Until recently, he was CEO and Chairman of the Board of the Actavis Group, a global integrated speciality pharmaceutical company, which became the third largest generics company worldwide...

Frances graduated from Magdalen, Oxford, in Biochemistry and immediately joined Savory Milln as a UK pharmaceuticals analyst. Following its takeover by Swiss Bank Corporation, she took up a role in pan-European pharmaceuticals coverage at IMI before moving to Nomura in 1994. At Nomura, she...

Mazen was appointed President and CEO of MENA and Emerging Markets in April 2014. Mazen was appointed group Executive Vice-Chairman and MENA CEO in 2005. During his 28 years’ service at Hikma, he has held an extensive range of positions within the Group starting as a medical representative and...

Pieter Dylst is a Health Economics Officer at the EGA since October 2014. As part of the Market Access team, he will work to shape in the EU a dynamic and sustainable market situation that enables fast and fair pricing and reimbursement for generic, biosimilar and value added medicines, thereby...

Rahul Garella is an experienced pharmaceutical executive with more than seventeen years of experience in the pharmaceutical business and a successful track record of creating and establishing new businesses across the segments of Active pharmaceutical ingredients (APIs) and finished dosage...

David Jauch is responsible for Government Relations within Global Regulatory Affairs of Fresenius Kabi. He is the Chair of the Trade Policy Committee, Member of the Board of European Generics and Biosimilars Medicines Association (EGA) as well as a member of several other Committees of the...

Amine Tahiri has18 years experience in global pharmaceutical industry. Until recently, he was in charge of commercial activities and products transfer of one of Recipharm manufacturing sites. Before, he was supply chain manager of Laboratoires Fournier and was working previously in Bristol-Myers...

Antonio López:antonio.lopez@recipharm.com+34608427889Business Director of Recipharm for Spain & Portugal. Pharmacist and MBA, 25 years of experience in pharmaceutical B2B, from API to FDF, and the whole supply chain, R&D, manufacturing and business.

After obtaining the academic title in 1995,Deepak started working in the pharmaceutical industry, holding increasingly more responsible positions in the field of development of pharmaceutical products at Wockhardt, Panacea Biotec and Ranbaxy. In 2006, he was appointed Head of Formulation Department ...

Apurva is currently Vice President of Global Operations and Business Development at Amneal Pharmaceuticals, based at the global headquarters in New Jersey, USA.  Apurva manages Amneal’s strategic and business development initiatives in the US and the execution of Amneal’s global expansion...

An excecutive with 15+ years international management experience in life science industry (medical device, pharma, biotech) and healthcare markets.  Accomplished million EUR targets from product development to commercialisation. Particular success in the set-up and management of complex projects...

Evert Jan van Lente studied economics in Amsterdam (Netherlands) and Goettingen (Germany) and is director EU-Affairs at the AOK, statutory Health Insurance Germany, -Federal Association. He is based in Brussels and Berlin. Until December 2013 he was Deputy Director of the Care Management /...

Peter Wittner, B.Sc., is an independent consultant specialising in the commercial aspects of generics with more than 30 years’ pharmaceutical experience. Most recently, he joined the Indian generic leader Ranbaxy as Managing Director to help set up its UK business before returning to consultancy...